Search

The impact of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) (initiated in 2000 in Ghana and ran for 12 years) in mitigating soil-transmitted helminth (STH) infections in LF-endemic areas is unknown. During a 1-year hiatus which ensued between 2011 and 2012, a longitudinal study was conducted to determine GPELF effect on hookworm infections in selected communities involved in the programme since its inception, while measuring the effectiveness of biannual ALB treatments on schoolchildren living in such communities. A total of 399 school children aged 3 to 18 years were randomly selected from four communities in the Kpandai district of northern Ghana. Each presented a single stool sample at baseline, 21 days post-treatment, at the 3rd and 6th months, 21 days post-second intervention (i.e. following sample collection and treatment with ALB in the 6th month), and in the ninth month of the study period. Haemoglobin (hb) levels were also measured at all time points using finger prick blood samples and a URIT digital test kit. Each participant submitting a sample, was treated with a single-dose ALB (400mg) at baseline and in the sixth month. Stool samples were processed by preparing duplicate Kato-Katz slides per sample, and examined by microscopy. The Body Mass Index-for-age z-scores (BAZ) of participants were assessed following the determination of BMIs at each time point by measuring their height and weight with a stadiometer and weighing scale. Overall hookworm prevalences were 25.68% (95% CI = 20.51–31.75) at baseline, 11.18% (95% CI = 7.87–15.41) 21 days post-treatment, 11.78% (95% CI = 8.38–16.11) and 6.95% (95% CI = 4.41–10.43) in the 3rd and 6th months, 0.91% (95% CI = 0.19–2.65) 21 days post-second intervention, and 8.46% (95% CI = 5.62–12.23) in the ninth month. Observed overall faecal egg count reduction rates (ERRs) were 94.21% (95% CI = 81.50%– 100.00%) 21 days after baseline treatment, 97.70% (95% CI = 85.08–100.00) and 96.95% (95% CI = 84.18%– 100.00%) in the 3rd and 6th months, 99.98% (95% CI = 86.42%– 100.00%) 21 days post-second intervention, and 17.18% (95% CI = 14.07%– 20.67%) in the 9th month. Respective cure rates (CRs) were 62.35% (95% CI = 46.71–81.56%), 85.88% (95% CI = 67.32–100.00%), 87.06% (95% CI = 68.36%– 100.00%), 98.82% (95% CI = 78.83%– 100.00%), and 36.36% (95% CI = 9.91%– 93.11%). Additionally, increases in the percent frequency of 'normal hb' (p < 0.01) were observed across the study time points, whilst 'normal BAZ' cases remained high (from 94.87% to 98.87%) throughout the study period. These findings primarily indicate satisfactory effectiveness of ALB which may be maintainable in mass drug administration programmes by the modification of treatment strategies from annual to bi-annual regimes. This could minimize the likelihood of emerging poorly-responding hookworm phenotypes in Ghana. Additionally, a positive impact of bi-annual treatment on participant anaemia status is herein indicated with particular regard to the school children in our cohort. [ABSTRACT FROM AUTHOR]

Background: Schistosomiasis remains a major public health issue with over 90% of the prevalence rates recorded in Sub-Saharan Africa. In this study, the relationships between different interleukin gene polymorphisms (IL-13-591A/G, IL-13-1055C/T, IL-13-1258A/G) and Schistosoma haematobium infection levels were evaluated; as well as the host plasma antibodies and cytokine profiles associated with schistosomiasis infection. Methodology: A total of 469 school children aged 6 to 19 years from four schistosomiasis-endemic communities in Ghana were involved. Single urine and stool samples were obtained from each pupil, processed via sedimentation and Kato-Katz, and examined via microscopy for Schistosoma and soil-transmitted helminth (STH) eggs. Next, venous blood samples were drawn from 350 healthy pupils, and used to measure antibody and plasma cytokine levels by ELISA. Single nucleotide polymorphisms in the IL-13 gene were genotyped on 71 selected blood samples using the Mass Array technique. Principal findings and conclusion: The overall prevalence of urinary schistosomiasis was 21.11%. Community-level prevalences were 17.12%, 32.11%, 20.80%, and 15.32% for Asempaneye, Barikumah, Eyan Akotoguah, and Apewosika respectively. Generally, higher S. haematobium infection prevalence and intensity were recorded for participants with genotypes bearing the IL13-1055C allele, the IL13-591A, and the IL13-1258A alleles. Also, higher S. haematobium infection prevalence was observed among participants in the 12-14-year age group with the IL13-1055C, IL13-591A, and IL13-1258A alleles. Interestingly, higher STH prevalence was also observed among participants with the IL13-1055C, IL13-591A, and IL13-1258A alleles. Furthermore, the age-associated trends of measured antibodies and cytokines of S. haematobium-infected school-children depicted a more pro-inflammatory immune profile for pupils aged up to 1l years, and an increasingly anti-inflammatory profile for pupils aged 12 years and above. This work provides insight into the influence of IL-13 gene polymorphisms on S. haematobium, and STH infections, in school-aged children (SAC). Author summary: Schistosomiasis is a neglected tropical disease with an estimated morbidity of 2.54 million disability-adjusted life years (DALYS), ranking it third among the parasitic diseases after Malaria and Dengue fever (WHO, 2018). About a decade ago, the World Health Organization (WHO) and its partners committed to intensifying efforts at increasing coverage during annual mass chemotherapy programmes in affected countries. This has influenced the reduction of the estimated disease-associated morbidity from 4.5 million DALYs in 2002 (WHO, 2002) to the current rate. Despite these gains, there is still growing concern that the persistent and extensive use of Praziquantel (PZQ) (the only approved chemotherapeutic agent) in these campaigns may lead to the development of poorly-responding phenotypes of Schistosoma sp. Strategies therefore to mitigate such possibilities may prove very advantageous, while research efforts towards the development of an effective vaccine continues. There has been growing evidence in recent years that infection of inhabitants in endemic areas may be influenced not only by environmental, but also by genetic factors as well. Of particular interest in this regard, is the region in the human genome, 5q31-q33, which bears several genes associated with immune function. One such group within this region is the T-helper 2 (Th2) cluster of genes, which are responsible for the production interleukin-4 (IL-4), IL-5, and IL-13 during immune response. We focused on single-nucleotide polymorphisms (SNPs) occurring in the IL-13 promoter region, particularly IL13-1055C/T, IL13-591A/G, and IL13-1258A/G, where we observed interesting trends with regard to participants' infection status in association with the polymorphisms they presented with. Also, we assessed their immune profiles after stratifying by age, and herein indicate trends which reflect observed age-associated trends between S. haematobium infection and the IL-13 polymorphisms. The outcomes presented indicate a need for further work which challenges the current 'one size fits all' strategy in mass chemotherapy programmes and advocates for participant-specific/sub-group tailored programmes. This is more likely to minimize the likelihood for the development of resistant Schistosoma strains to PZQ. [ABSTRACT FROM AUTHOR]

We recently developed a superhydrophobic cone-based method for the collection of mosquito excreta/feces (E/F) for the molecular xenomonitoring of vector-borne parasites showing higher throughput compared to the traditional approach. To test its field applicability, we used this platform to detect the presence of filarial and malaria parasites in two villages of Ghana and compared results to those for detection in mosquito carcasses and human blood. We compared the molecular detection of three parasites (Wuchereria bancrofti, Plasmodium falciparum and Mansonella perstans) in mosquito E/F, mosquito carcasses and human blood collected from the same households in two villages in the Savannah Region of the country. We successfully detected the parasite DNA in mosquito E/F from indoor resting mosquitoes, including W. bancrofti which had a very low community prevalence (2.5–3.8%). Detection in the E/F samples was concordant with detection in insect whole carcasses and human blood, and a parasite not vectored by mosquitoes was detected as well.Our approach to collect and test mosquito E/F successfully detected a variety of parasites at varying prevalence in the human population under field conditions, including a pathogen (M. perstans) which is not transmitted by mosquitoes. The method shows promise for further development and applicability for the early detection and surveillance of a variety of pathogens carried in human blood. Author summary: Molecular xenomonitoring of parasites or viruses using mosquitoes as "flying syringes" is a promising and non-invasive tool for early detection and surveillance of various pathogens, particularly in low prevalence settings, but there is a need for cost-effective and higher throughput alternatives. We recently developed a novel approach based on the collection of mosquito excreta/feces (E/F) using a superhydrophobic cone that directs the sample into a tube at the bottom of the collection cup. We tested this method's ability to detect the presence of filarial and malaria parasite DNA from households in two endemic rural communities of Ghana and compared it to the molecular detection from blood and mosquito carcass samples from corresponding households. The detection of parasite DNA in mosquito E/F was successful for all three pathogens, and it showed good concordance with the detection in the insects' whole carcasses. Given the successful detection of Mansonella perstans, which is not transmitted by mosquitoes, our tool shows promise for use as an alternative method for the early and non-invasive detection and surveillance of various pathogens in human blood, including those not strictly mosquito-borne, in endemic settings. [ABSTRACT FROM AUTHOR]

Background: Despite the progress achieved in scaling-up mass drug administration (MDA) for lymphatic filariasis (LF) in Ghana, communities with persistent LF still exist even after 10 years of community treatment. To understand the reasons for persistence, we conducted a study to assess the status of disease elimination and understand the adherence to interventions including MDA and insecticide treated nets. Methodology and principal findings: We conducted a parasitological and epidemiological cross-sectional study in adults from eight villages still under MDA in the Northern Region savannah and the coastal Western Region of the country. Prevalence of filarial antigen ranged 0 to 32.4% and in five villages the prevalence of night blood microfilaria (mf) was above 1%, ranging from 0 to 5.7%. Median mf density was 67 mf/ml (range: 10–3,560). LF antigen positivity was positively associated with male sex but negatively associated with participating in MDA the previous year. Male sex was also associated with a decreased probability of participating in MDA. A stochastic model (TRANSFIL) was used to assess the expected microfilaria prevalence under different MDA coverage scenarios using historical data on one community in the Western Region. In this example, the model simulations suggested that the slow decline in mf prevalence is what we would expect given high baseline prevalence and a high correlation between MDA adherence from year to year, despite high MDA coverage. Conclusions: There is a need for an integrated quantitative and qualitative research approach to identify the variations in prevalence, associated risk factors and intervention coverage and use levels between and within regions and districts. Such knowledge will help target resources and enhance surveillance to the communities most at risk and to reach the 2020 LF elimination goals in Ghana. [ABSTRACT FROM AUTHOR]

Background: It has been proposed that switching from annual to biannual (twice yearly) mass community-directed treatment with ivermectin (CDTI) might improve the chances of onchocerciasis elimination in some African foci. However, historically, relatively few communities have received biannual treatments in Africa, and there are no cost data associated with increasing ivermectin treatment frequency at a large scale. Collecting cost data is essential for conducting economic evaluations of control programmes. Some countries, such as Ghana, have adopted a biannual treatment strategy in selected districts. We undertook a study to estimate the costs associated with annual and biannual CDTI in Ghana. Methodology: The study was conducted in the Brong-Ahafo and Northern regions of Ghana. Data collection was organized at the national, regional, district, sub-district and community levels, and involved interviewing key personnel and scrutinizing national records. Data were collected in four districts; one in which treatment is delivered annually, two in which it is delivered biannually, and one where treatment takes place biannually in some communities and annually in others. Both financial and economic costs were collected from the health care provider's perspective. Principal Findings: The estimated cost of treating annually was US Dollars (USD) 0.45 per person including the value of time donated by the community drug distributors (which was estimated at USD 0.05 per person per treatment round). The cost of CDTI was approximately 50–60% higher in those districts where treatment was biannual than in those where it was annual. Large-scale mass biannual treatment was reported as being well received and considered sustainable. Conclusions/Significance: This study provides rigorous evidence of the different costs associated with annual and biannual CDTI in Ghana which can be used to inform an economic evaluation of the debate on the optimal treatment frequency required to control (or eliminate) onchocerciasis in Africa. Author Summary: The African Programme for Onchocerciasis Control (APOC) has recently been extended until 2025, with renewed commitment towards onchocerciasis elimination. This aim is aligned with the goals stated by the World Health Organization and the London Declaration on Neglected Tropical Diseases in January 2012. Switching from annual to biannual (twice yearly) ivermectin distribution might increase the feasibility of onchocerciasis elimination in some African foci. However, relatively few communities have received biannual treatments in Africa, and there are no cost data associated with increasing ivermectin treatment frequency at a large scale, essential pre-requisites to provide reliable information for evidence-based decision making regarding adoption of a biannual treatment strategy. Therefore, we undertook a study to estimate costs associated with biannual compared to annual ivermectin delivery in Ghana, which since 2009 has implemented a biannual treatment strategy in selected priority areas. Our results indicate that the cost of biannual ivermectin treatment per year is approximately 60% higher than the cost of annual treatment. This study provides tangible evidence of the different costs associated with annual and biannual ivermectin treatment, which can be used to inform economic evaluations and policy decisions regarding the optimal treatment frequency required to eliminate onchocerciasis in Africa. [ABSTRACT FROM AUTHOR]